Conclusions
The increased risk of HDP in srPCOS can mostly be attributed to
overweight/obesity and weight gain through life. Importantly, normal
weight women with srPCOS were not at increased risk for developing HDP.
The present results emphasize the importance of weight management prior
pregnancy to reduce the incidence of HDP, an important factor cause of
postnatal morbidity. The role of hyperandrogenaemia in the
pathophysiological process of HDP could not be confirmed, remaining
under debate with further research being needed to clarify its role.
Disclosure of interests
None
Contribution to authorship
L.C.M.-P., S.I.W., J.N and J.S.S.R conceived and designed the study.
A.H.B. and J.S.S.R. analysed the data and L.M.C.-P., J.N. and M.S.V
contributed to its interpretation. J.S.S.R. and J.N drafted the
manuscript. M.-M.E.O, K.P, M.-R.J, J.S.T, S.F and T.T.P participated in
the revision process and have approved this submission for publication.
Details of ethics approval
The study followed the principles of the Declaration of Helsinki. The
Ethics Committee of the Northern Ostrobothnia Hospital District (EETTMK
decision number 94/2011) has approved the research on Sebtember
17th, 2012. All participants took part on a voluntary
basis and signed an informed consent to use all data.
Grants and funding: This work was supported by grants from the Finnish
Medical Foundation, the North Ostrobothnia Regional Fund, Academy of
Finland (project grants 315921, 104781, 120315, 129269, 1114194,
24300796, 295760), Center of Excellence in Complex Disease Genetics and
SALVE, the Sigrid Juselius Foundation, University Hospital Oulu and
University of Oulu (75617), Medical Research Center Oulu, National
Institute for Health Research (UK), Genesis Research Trust (UK), NHLBI
grant 5R01HL087679-02 through the STAMPEED program (1RL1MH083268-01),
NIH/NIMH (5R01MH63706:02), ENGAGE project and grant agreement
HEALTH-F4-2007-201413, EU FP7 EurHEALTHAgeing -277849 the European
Commission and the Medical Research Council, UK (G0500539, G0600705,
G1002319, G0802782, PrevMetSyn/SALVE) and the MRC, Centenary Early
Career Award.
The study is not supported or sponsored by any commercial organisation,
grant, or fund.
Supporting Information
Additional Supporting Information may be found in the online version of
this article:
Figure S1. Flowchart of the HDP
diagnosis.
Figure S2. Prevalence of hypertensive disorders of pregnancy (HDP) in
different total level of testosterone (A) and free androgen (B)
quartiles at ages 31 and 46
References
(1) Archer JS, Chang RJ. Hirsutism and acne in polycystic ovary
syndrome. Best Practice & Research in Clinical Obstetrics &
Gynaecology 2004 Oct;18(5):737-754.
(2) Franks S. Polycystic ovary syndrome. N Engl J Med 1995 Sep
28;333(13):853-861.
(3) Kjerulff LE, Sanchez-Ramos L, Duffy D. Pregnancy outcomes in women
with polycystic ovary syndrome: a metaanalysis. Am J Obstet Gynecol 2011
Jun;204(6):558.e1-558.e6.
(4) Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group.
Revised 2003 consensus on diagnostic criteria and long-term health risks
related to polycystic ovary syndrome. Fertil Steril 2004
Jan;81(1):19-25.
(5) Teede H, Missio M, Costello M, Dokras A, Laven J, Moran L, et al.
Recommendations from the international evidence-based guideline for the
assessment and management of polycystic ovary syndrome. Human
Reproduction 2019;34(2):388.
(6) Sam S. Obesity and Polycystic Ovary Syndrome. Obes Manag 2007
Apr;3(2):69-73.
(7) Lim SS, Kakoly NS, Tan JWJ, Fitzgerald G, Bahri Khomami M, Joham AE,
et al. Metabolic syndrome in polycystic ovary syndrome: a systematic
review, meta-analysis and meta-regression. Obes Rev 2019
Feb;20(2):339-352.
(8) Diamanti-Kandarakis E. Role of obesity and adiposity in polycystic
ovary syndrome. Int J Obes (Lond) 2007 discussion S31-2; Nov;31(Suppl
2):S8-13.
(9) Hashemi S, Ramezani Tehrani F, Mehrabi Y, Azizi F. Hypertensive
pregnancy disorders as a risk factor for future cardiovascular and
metabolic disorders (Tehran Lipid and Glucose Study). Journal of
Obstetrics & Gynaecology Research 2013 May;39(5):891-897.
(10) American College of Obstetricians and Gynecologists, Task Force on
Hypertension in Pregnancy. Hypertension in pregnancy. Report of the
American College of Obstetricians and Gynecologists’ Task Force on
Hypertension in Pregnancy. Obstet Gynecol 2013 Nov;122(5):1122-1131.
(11) Davison JM, Homuth V, Jeyabalan A, Conrad KP, Karumanchi SA,
Quaggin S, et al. New aspects in the pathophysiology of preeclampsia.
Journal of the American Society of Nephrology 2004 Sep;15(9):2440-2448.
(12) Wang Y, Zhao X, Zhao H, Ding H, Tan J, Chen J, et al. Risks for
gestational diabetes mellitus and pregnancy-induced hypertension are
increased in polycystic ovary syndrome. BioMed Research International
2013;2013:182582.
(13) Mannisto T, Mendola P, Vaarasmaki M, Jarvelin M, Hartikainen A,
Pouta A, et al. Elevated blood pressure in pregnancy and subsequent
chronic disease risk. Circulation 2013 Feb 12;127(6):681-690.
(14) Herrera-Garcia G, Contag S. Maternal preeclampsia and risk for
cardiovascular disease in offspring. Curr Hypertens Rep 2014
Sep;16(9):475.
(15) Bahri Khomami M, Joham AE, Boyle JA, Piltonen T, Silagy M, Arora C,
et al. Increased maternal pregnancy complications in polycystic ovary
syndrome appear to be independent of obesity-A systematic review,
meta-analysis, and meta-regression. Obes Rev 2019 May;20(5):659-674.
(16) Boomsma CM, Eijkemans MJC, Hughes EG, Visser GHA, Fauser BCJM,
Macklon NS. A meta-analysis of pregnancy outcomes in women with
polycystic ovary syndrome. Hum Reprod Update 2006 Nov-Dec;12(6):673-683.
(17) Qin JZ, Pang LH, Li MJ, Fan XJ, Huang RD, Chen HY. Obstetric
complications in women with polycystic ovary syndrome: a systematic
review and meta-analysis. Reprod Biol Endocrinol 2013 Jun 26;11:56.
(18) Altieri P, Gambineri A, Prontera O, Cionci G, Franchina M, Pasquali
R. Maternal polycystic ovary syndrome may be associated with adverse
pregnancy outcomes. Eur J Obstet Gynecol Reprod Biol 2010
Mar;149(1):31-36.
(19) Haakova L, Cibula D, Rezabek K, Hill M, Fanta M, Zivny J. Pregnancy
outcome in women with PCOS and in controls matched by age and weight.
Hum Reprod 2003 Jul;18(7):1438-1441.
(20) Mikola M, Hiilesmaa V, Halttunen M, Suhonen L, Tiitinen A.
Obstetric outcome in women with polycystic ovarian syndrome. Human
Reproduction 2001 Feb;16(2):226-229.
(21) Mumm H, Jensen DM, Sørensen JA, Andersen LLT, Ravn P, Andersen M,
et al. Hyperandrogenism and phenotypes of polycystic ovary syndrome are
not associated with differences in obstetric outcomes. Acta Obstet
Gynecol Scand 2015 02/01; 2019/01;94(2):204-211.
(22) Ollila ME, Piltonen T, Puukka K, Ruokonen A, Jarvelin M, Tapanainen
JS, et al. Weight Gain and Dyslipidemia in Early Adulthood Associate
With Polycystic Ovary Syndrome: Prospective Cohort Study. J Clin
Endocrinol Metab 2016 Feb;101(2):739-747.
(23) Koivuaho E, Laru J, Ojaniemi M, Puukka K, Kettunen J, Tapanainen
JS, et al. Age at adiposity rebound in childhood is associated with PCOS
diagnosis and obesity in adulthood-longitudinal analysis of BMI data
from birth to age 46 in cases of PCOS. Int J Obes (Lond) 2019
Jul;43(7):1370-1379.
(24) Koivunen R, Pouta A, Franks S, Martikainen H, Sovio U, Hartikainen
A, et al. Fecundability and spontaneous abortions in women with
self-reported oligo-amenorrhea and/or hirsutism: Northern Finland Birth
Cohort 1966 Study. Hum Reprod 2008 Sep;23(9):2134-2139.
(25) Rantakallio P. The longitudinal study of the northern Finland birth
cohort of 1966. Paediatr Perinat Epidemiol 1988 Jan;2(1):59-88.
(26) Taponen S, Ahonkallio S, Martikainen H, Koivunen R, Ruokonen A,
Sovio U, et al. Prevalence of polycystic ovaries in women with
self-reported symptoms of oligomenorrhoea and/or hirsutism: Northern
Finland Birth Cohort 1966 Study. Hum Reprod 2004 May;19(5):1083-1088.
(27) ZAWADSKI JK DA. Diagnostic criteria for polycystic ovary syndrome:
towards a rational approach. In: DUNAIF AGJ, HASELTINE F, EDS.
Polycystic Ovary Syndrome. 1992;377-384.(Boston: Blackwell Scientific).
(28) Taponen S, Martikainen H, Jarvelin M, Laitinen J, Pouta A,
Hartikainen A, et al. Hormonal profile of women with self-reported
symptoms of oligomenorrhea and/or hirsutism: Northern Finland birth
cohort 1966 study. Journal of Clinical Endocrinology & Metabolism 2003
Jan;88(1):141-147.
(29) Hutcheon JA, Lisonkova S, Joseph KS. Epidemiology of pre-eclampsia
and the other hypertensive disorders of pregnancy. Best Pract Res Clin
Obstet Gynaecol 2011 Aug;25(4):391-403.
(30) Umesawa M, Kobashi G. Epidemiology of hypertensive disorders in
pregnancy: prevalence, risk factors, predictors and prognosis. Hypertens
Res 2017 Mar;40(3):213-220.
(31) Ye C, Ruan Y, Zou L, Li G, Li C, Chen Y, et al. The 2011 survey on
hypertensive disorders of pregnancy (HDP) in China: prevalence, risk
factors, complications, pregnancy and perinatal outcomes. PLoS ONE
2014;9(6):e100180.
(32) Fuchs F, Senat M, Rey E, Balayla J, Chaillet N, Bouyer J, et al.
Impact of maternal obesity on the incidence of pregnancy complications
in France and Canada. Sci rep 2017 Sep 07;7(1):10859.
(33) Lonnebotn M, Natvig GK, Benediktsdottir B, Burgess JA, Holm M, Jogi
R, et al. Polycystic ovary syndrome, body mass index and hypertensive
disorders in pregnancy. Pregnancy Hypertens 2018 Jan;11:32-37.
(34) Palomba S, Falbo A, Russo T, Tolino A, Orio F, Zullo F. Pregnancy
in women with polycystic ovary syndrome: the effect of different
phenotypes and features on obstetric and neonatal outcomes. Fertil
Steril 2010 Oct;94(5):1805-1811.
(35) Naver KV, Grinsted J, Larsen SO, Hedley PL, Jorgensen FS,
Christiansen M, et al. Increased risk of preterm delivery and
pre-eclampsia in women with polycystic ovary syndrome and
hyperandrogenaemia. BJOG 2014 Apr;121(5):575-581.
(36) Carlsen SM, Romundstad P, Jacobsen G. Early second-trimester
maternal hyperandrogenemia and subsequent preeclampsia: a prospective
study. Acta Obstet Gynecol Scand 2005 Feb;84(2):117-121.
(37) Perez-Sepulveda A, Monteiro LJ, Dobierzewska A, Espana-Perrot PP,
Venegas-Araneda P, Guzman-Rojas AM, et al. Placental Aromatase Is
Deficient in Placental Ischemia and Preeclampsia. PLoS ONE
2015;10(10):e0139682.
(38) Ghorashi V, Sheikhvatan M. The relationship between serum
concentration of free testosterone and pre-eclampsia. Endokrynol Pol
2008 Sep-Oct;59(5):390-392.
(39) Hakim C, Padmanabhan V, - Vyas,Arpita K. - Gestational
Hyperandrogenism in Developmental Programming. - Endocrinology February
1, 158(2):199 2017 - 2016.
(40) Karjula S, Morin-Papunen L, Auvinen J, Ruokonen A, Puukka K, Franks
S, et al. Psychological Distress Is More Prevalent in Fertile Age and
Premenopausal Women With PCOS Symptoms: 15-Year Follow-Up. J Clin
Endocrinol Metab 2017 Jun 1;102(6):1861-1869.
Table 1 Clinical
characteristics of non-PCOS women and women with srPCOS, sorted
according to status of hypertensive disorder of pregnancy.